Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Tango Therapeutics (TNGX) Return on Equity (2021 - 2025)

Tango Therapeutics has reported Return on Equity over the past 5 years, most recently at 0.4% for Q4 2025.

  • Quarterly results put Return on Equity at 0.4% for Q4 2025, up 21.0% from a year ago — trailing twelve months through Dec 2025 was 0.4% (up 21.0% YoY), and the annual figure for FY2025 was 0.37%, up 20.0%.
  • Return on Equity for Q4 2025 was 0.4% at Tango Therapeutics, up from 0.68% in the prior quarter.
  • Over the last five years, Return on Equity for TNGX hit a ceiling of 0.16% in Q4 2021 and a floor of 0.96% in Q2 2025.
  • Median Return on Equity over the past 5 years was 0.44% (2024), compared with a mean of 0.49%.
  • Biggest five-year swings in Return on Equity: skyrocketed 59bps in 2022 and later plummeted -51bps in 2025.
  • Tango Therapeutics' Return on Equity stood at 0.16% in 2021, then plummeted by -152bps to 0.41% in 2022, then grew by 7bps to 0.38% in 2023, then tumbled by -58bps to 0.61% in 2024, then skyrocketed by 34bps to 0.4% in 2025.
  • The last three reported values for Return on Equity were 0.4% (Q4 2025), 0.68% (Q3 2025), and 0.96% (Q2 2025) per Business Quant data.